drugset / Trial / NCT06251973
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
NaSingle-groupOpen-labelTreatment
Summary
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | — | Intravenous |
| Subject | Botensilimab | Monoclonal antibody | — | — |
| Subject | agenT-797 | Cell therapy | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Ramucirumab | Monoclonal antibody | — | — |